Business
Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma
-- Providing an end-to-end business solution for our customers -- Ensuring seamless integration of drug and light combination for both physicians and patients
About this update from Soligenix, Inc.
[{"type":"text","content":"-- Providing an end-to-end business solution for our customers\n -- Ensuring seamless integration of drug and light combination for both physicians and patients\n\n\nPRINCETON, N.J., Jan. 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has signed an exclusive Supply, Distribution and Services Agreement with Daavlin. Securing long-term supply and distribution of a commercially ready light device is an integral component of the regulatory and commercial strategy for SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). \nDaavlin has a 40-year history of innovation and development in the field of phototherapy, providing an extensive line of products and services to health care providers and patients worldwide for the purposes of treating photoresponsive skin disorders such as psoriasis, vitiligo and now CTCL. The company's corporate headquarters and manufacturing plant are located in Bryan, Ohio. \nPursuant to the Agreement, Daavlin will exclusively manufacture the proprietary light device for use with SGX301 for the treatment of CTCL. Upon approval of SGX301 by the US Food and Drug Administration (FDA), Soligenix will promote SGX301 and the companion light device, and facilitate the direct purchase of the device from Daavlin; and Daavlin will exclusively distribute and sell the SGX301 light device to Soligenix, physicians and patients. \n\"We are pleased to be partnering with a company like Soligenix that has such deep expertise in development of products for treating rare diseases such as CTCL,\" said Dave Swanson, Founder and Chief Executive Officer of Daavlin, \"Our extensive history in the commercialization of phototherapy medical devices in both the US and Europe complements Soligenix as they bring SGX301 to CTCL patients in need.\"\n\"Daavlin brings technical, manufacturing and commercial capabilities in both the US and Europe that will assist us in rapidly and efficiently distributing the SGX301 companion light device upon approval by FDA,\" stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. \"Seamless integration of the drug product and companion ligh...